Diagnostics company bioMerieux (PARIS:BIM) has received 510(k) clearance from the U.S. Food and Drug Administration for a test to detect and screen for methicillin-resistant staphylococcus, more ...
Company Offers Most Comprehensive, Cost-Effective Suite of Solutions to Detect and Screen for Methicillin Resistant Staphylococcus aureus (MRSA) “bioMérieux is committed to bringing innovative ...
France's bioMerieux is looking to solidify its position as a leader in the field of in vitro diagnostics through acquisitions and diagnostic tests to detect superbugs, hospital acquired infections and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results